GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytomX Therapeutics Inc (STU:6C1) » Definitions » Total Equity

CytomX Therapeutics (STU:6C1) Total Equity : €-29.1 Mil (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is CytomX Therapeutics Total Equity?

CytomX Therapeutics's total equity for the quarter that ended in Mar. 2024 was €-29.1 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

CytomX Therapeutics Total Equity Historical Data

The historical data trend for CytomX Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytomX Therapeutics Total Equity Chart

CytomX Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.00 -6.39 -0.41 -80.95 -43.51

CytomX Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -80.92 -78.48 -48.01 -43.51 -29.15

CytomX Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

CytomX Therapeutics's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=185.043-228.552
=-43.5

CytomX Therapeutics's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=169.912-199.058
=-29.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytomX Therapeutics Total Equity Related Terms

Thank you for viewing the detailed overview of CytomX Therapeutics's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

CytomX Therapeutics (STU:6C1) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytomX Therapeutics Inc (STU:6C1) » Definitions » Total Equity
Comparable Companies
CCCC KOD ACXP ANVS CLDI VTGN ORMP CSBR STTK OMER OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
CTMX:USA 6C1:Germany
Address
151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Website
https://www.cytomx.com
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

CytomX Therapeutics (STU:6C1) Headlines

No Headlines